Interleukin-6 and TNFα production in human renal cell carcinoma  by Gogusev, Jean et al.
Kidney International, Vol. 44 (1993), pp. 585—592
Interleukin-6 and TNFa production in human renal cell
carcinoma
JEAN GOGUSEV, MICHEL AuGusT!, YVES CHRETIEN, and DOMINIQUE DROZ
INSERM U90; Clinique Urologique, Pr. Cukier; Clinique Urologique, Pr. Dufour; and Laboratoire de Pathologie Rénale, Hôpital Necker,
Paris, France
Interleukin-6 and TNFa production in human renal cell carcinoma.
Several clinical and biological features suggest that cytokines impli-
cated in the inflammatory response are produced by renal cell carci-
noma (RCC). To define if alterations of tumor necrosis factor alpha
(TNFa), interleukin I alpha (IL-la), IL-lf3 and IL-6 gene expression
are present in this malignancy, samples from 19 tumors as well as
samples from seven paired normal renal tissue were examined using
Northern blot and immunohistochemical analysis. In addition, the
expression of these cytokines was evaluated in seven RCC-derived cell
cultures using Northern blot or RT-PCR. TNFa and IL-6 proteins were
measured in culture supernatants using specific bio- and immunoassays.
Consistent levels of IL-6 mRNA were detected in 17 of the 19 tested
tumors whereas TNFa specific transcripts were present in seven of
eight available RNA samples. TNFa and IL-6 mRNA were also
detected in five of the seven paired normal kidneys. By immunolabel-
ing, IL-6 antigen was not detected in RCC cells in any of the 19 studied
samples. In contrast, using anti-TNFa antibody a strong labeling of
stromal endothelia and macrophage cells was detected in all the 19
cases, and evident TNFa staining of the carcinoma cells themselves
was observed in eight cases. Spontaneous IL-6 mRNA expression was
detected in five RCC cell cultures and TNFa mRNA in four. The
cultured cells exhibited positive TNFa immunolabeling in six of seven
cases but were always IL-6 negative. Bioactive IL-6 was detected in all
culture supernatants while bioactive TNFa was not detected. However,
immunoreactive TNFa protein was measured in two of three superna-
tants tested. Altogether these data indicate that RCC cells produce
TNFa and IL-6 in vivo and in vitro at the RNA and protein level.
Renal cell carcinomas (RCC) are the most frequent kidney
tumors in adults. Recent studies have described cell differenti-
ation in these tumors, suggesting that clear cell type carcinomas
differentiate more or less towards the proximal tubule, whereas
basophilic cell type carcinomas share similarities with the
blastematous tubules [1—6]. It is well known that growing RCC
almost always present areas of necrosis and of hemorrhage
even when the tumors are of small size, and comprise abundant
inflammatory cells in the stroma [7]. Clinically, RCC may be
associated with fever, increased acute phase reactant blood
proteins in serum and, in some cases, with secondary AA
amyloidosis [7]. These features suggest, as has been observed
in other human tumors, that RCC may produce increased levels
of tumor necrosis factor alpha (TNFa), interleukin- 1 and -6
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(IL-I and IL-6) cytokines known to be implicated in the
inflammatory response. In this regard it has been reported that
IL-6, TNFx, IL-la and IL-113 genes are expressed in normal
renal tissue at the RNA level [8]. More recently, IL-6 expres-
sion has been observed in RCC and it has been suggested that
IL-6 may act as a growth factor in these tumors [9—I 1].
The aim of the present study was to determine whether the
synthesis of these cytokines (TNFa, IL-i, IL-6) occurs in RCC
and to define the cell type involved in that production. There-
fore, we examined the expression of the specific mRNA for
each cytokine on one hand and their tissular localization on the
other hand, in neoplastic and normal kidney specimens. On the
basis of the RCC features observed in vivo, we studied in a
second step, the production of TNFa and IL-6 by tumor-
derived cell cultures using Northern blot and RT-PCR, immu-
nocytochemistry and specific assays.
Methods
Tumor samples
Nineteen renal cell carcinomas obtained from total nephrec-
tomy were examined including 17 cases of clear cell type and
two tubulopapillary carcinomas with basophilic cells. Speci-
mens from the tumorous areas were frozen in isopentane
precooled by liquid nitrogen. In seven cases a nontumorous
area, taken at the opposite pole of the same kidney, was studied
using the same procedures.
Tumor derived cell cultures
Cell cultures were obtained from seven tumors [6 clear cell
type RCC and one tubulopapillary RCC (case no. 5, Table 1)].
Immediately after surgical removal, a fragment (1 cm3) of the
tumoral mass chosen in a non-necrotic area was minced and
trypsinized to obtain single cell suspension. These cells were
cultured in complete medium consisting of RPMI-1640 medium
supplemented with 10% fetal calf serum, 100 U/mI of penicillin,
100 dIml of streptomycin and 2 mt L-glutamine. Initial com-
plete growth medium contained insulin 5 g/ml and 10 nglml of
EGF. The last two additives were removed from the medium
after the second passage. The renal epithelial nature of the RCC
cultures was confirmed by immunostaining for cytokeratin,
vimentin, and CD24 as previously described [6]. Human skin
fibroblasts cultured under the same conditions were used as
controls.
585
586 Gogusev et a!: Cytokine expression in renal cell carcinoma
Table 1. Immunocytochemical, mRNAs cytokine expression and supernatants bio and immunoassays in 7 RCC derived cell cultures (cases
1—4, 6 and 7 derived from clear cell type RCC and case 5 derived from tubulopapillary RCC)
Tumoral cell cultures
Immunocytochemistry
IL-6
mRNA
TNFa
Supernatants
Bioassays U/mi
IL-6 TNFa
ELISA
TNFa
pg/miCase CytoK vim CD24 IL-6 TNFs
I
2
3
4
5
6
7
Fibroblasts
+
—
+
-i-
+
+
+
0
+ + 0
ND + 0
ND + 0
+ + 0
+ + 0
+ + 0
+ + 0
+ 0 0
+
+
+
+
+
+
0
0
0
+
+
0a
+a
i-°
0
0
0
+
a
÷a
>1400 0
> 620 0
>500 0
>1000 0
> 500 0
> 500 0
>500 0
ND
ND
ND
ND
24
74
0
Abbreviations are: cytoK, cytokeratin; vim, vimentin; ND, not determined.
a RT-PCR
Isolation of RNA, Northern blot and RT-PCR
Total cellular and tissue RNA were purified by the guanidin-
ium isothyocyanate/cesium chloride method as described by
Chirgwin et al [121, followed by precipitation with 3 M sodium
acetate and ethanol. Concentration and purity were determined
by absorbance at 260 and 280 nm. The integrity of total RNA
was evaluated after fractionation of ethidium bromide stained
RNA bands on 1% agarose gel electrophoresis containing 2.2 M
formaldehyde.
For Northern blot analysis, aliquots (20 jzg) of total cellular
RNA were electrophoresed through 1% agarose-formaldehyde
gels followed by transfer to nylon membranes (Hybond, Amer-
sham, UK) and hybridization with appropriate probes. The
following cDNA fragments were used: the 1.1 kb Pst I fragment
of PE4 plasmid containing human TNFa cDNA insert [13], the
1.7 kb IL-i a cDNA obtained from Xho I digested pXM plas-
mid, the 1.3kb IL-1f3 insert obtained by Pst I digestion of pSP64
vector, the 1.2 kb IL-6 fragment obtained by EcoRI digestion of
pM2T vector, and the chicken 13-actin cDNA purified from PA!
plasmid [14]. All probes were labeled with 32P dCTP using the
multiprime DNA labeling system (Amersham, UK) as de-
scribed by Feinberg and Vogeslstein [15]. The membranes were
prehybndized at 42°C for 12 hours in buffer consisting of 50%
formamide, 5 x standard saline citrate (SSC) (0.15 M NaC1;
0.015 M Na3 citrate = 1 x SSC), 0.1% SDS, 5 x Denhardt's
solution and 200 jxg/ml salmon sperm DNA. The filters were
then incubated for an additional 16 hours in the same buffer with
2 x 106 cmp/ml of labeled probe. After hybridization, the blots
were washed twice in 0.1% SDS, 2 x SSC for 60 minutes at
room temperature, and then washed two more times with 0.1%
SDS, 0.1 x SSC at 55°C. The blots were then dried and exposed
to X-ray films for 12 to 24 hours with an intensifying screen at
—80°C.
Reverse transcription of 1 g of total cellular RNA was
performed using superscript reverse transcriptase and random
primers according to the manufacturer's instructions (Gibco-
BRL, Bethesda, Maryland, USA). The obtained cDNA was
processed for PCR using TNFa and IL-6 specific primers
purchased from Stratagene (La Jolla, California, USA) at a final
concentration of 1 LM. PCR reaction was achieved in a final
volume of 100 p1(1 cycle at 94°C for 5 mm and 5 mm at 60°C),
followed by 30 cycles of 1.5 minutes at 72°C, 45 seconds at 94°C
and 45 seconds at 60°C, with a final extension of 10 minutes at
72°C.
In order to assess specificity of the hybridization signal,
RNAs extracted from phorbol ester stimulated hematopoietic
DEL cell line, expressing TNFa, IL-la, IL-l/3 and IL-6 were
used as positive control.
Immunohistochemistry
Cryostat sections (2 p1 were fixed in methanol for 10 minutes
and processed using an indirect immunoperoxidase technique
as described previously [6]. Cell cultures for immunolabeling
were plated in microwell chamber slides (LabTek chambers,
NUNC Inc., Illinois, USA) at a density of 1 x io cells/mi.
Growing cells were arrested at 80 to 90% confluence, washed in
PBS, and after fixation in cold methanol (10 mm) used for
immunocytochemical staining.
The following primary antibodies (ab) were used: monoclonal
anti-CD14 (macrophages) from Becton-Dickinson; monoclonal
anti-CD35 (CR1), monoclonal anti-CDS7 specific for natural
killer (NK) cells and monoclonal anti-endothelial F-Vu! antigen
from Immunotech (Luminy, France). Rabbit polyclonal abs
anti-human TNFa (IP-3!0), anti-human IL-I (EP-200) and anti-
human IL-6 (LP-716) were purchased from Genzyme (Cam-
bridge, Massachusetts, USA). EP-200 ab consisted of anti-
IL-i a and anti-IL-!j3 in approximately a 1:3 mixture. Anti-
TNFa ab was used at a dilution of 1/160° and anti-IL-i and
anti-IL-6 at a dilution of 1/20°.
Monoclonal abs were revealed using rabbit anti-mouse and
goat anti-rabbit IgG peroxydase conjugated antibodies (Dako,
Denmark). For polyclonal ab we used goat anti-rabbit peroxy-
dase conjugated IgG (Dako). Sections incubated with PBS or
with normal rabbit IgG and second ab were used in each case as
negative controls.
IL-6 and TNFa assays
IL-6 bioactivity of RCC culture supernatants was measured
using the IL-6 dependent murine hybridoma cell line B9 [16,
171. Proliferation of the B9 cells was determined by the MT1'
colorimetric assay as described by Mosmann [18]. The speci-
ficity of the B9 response to IL-6 was tested with a polyclonal
a b C de t g h
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Fig. 2. Northern blotanalysis of TNFa and IL-6 mRNA content from
8 primary RCC. The membrane was hybridized with IL-6, TNFa and
13-actin probes. No TNFa transcripts were detected in lane b and there
was a weak signal in lane e. Supplementary bands of lower molecular
weight are due to nonspecific hybridization signals.
Fig. 1. Expression of TNFa and IL-6 mRNA inS normal kidneys (NK).
Total cellular RNA (20 sg) extracted from primary tissue was fraction-
ated on 1% agarose/formaldehyde gels, transferred to nylon membrane
and hybridized to 32P-labeled TNFa and IL-6 cDNA probes. The same
membrane was rehybridized with /3-actin cDNA.
anti-human IL-6 antibody. In the neuralization experiments,
supernatants collected five days after passage were incubated
during four hours at 37°C with a concentration of 2 pg/ml of the
anti-IL-6 ab or murine unrelated immunoglobulin antibody as
control. In these conditions we found that this antibody abro-
gated the biological activity mediated by more then 100 pg/ml of
rHu IL-6.
TNFa was evaluated in culture supernatants using bio- and
immunoassays. The biological activity of TNFa was deter-
mined on actinomycin D-treated murine L929 cells as described
[19]. Immunoreactive TNFa protein was measured using spe-
cific ELISA kit with detection limit at 15 pg/ml (Medgenics,
Fleurus, Belgium).
Results
Cytokine gene expression
Nondegraded RNA material was obtained from five of the
seven normal kidney fragments. After hybridization with spe-
cific probes, transcripts corresponding to IL-6 and TNFa were
detected in all five cases (Fig. 1). In contrast, lower levels of
IL-1f3 mRNAs were detected in three of five while IL-la
transcripts were not observed (data not shown).
To evaluate the presence of IL-6 mRNA in tumors, total
RNAs extracted from nineteen RCC samples were hybridized
with IL-6 specific probe. Specific transcript of 1.6 kb was
detected in 17 of 19 samples, including 16 of clear cell type and
one of basophilic cell type tumors. Eight available RNAs
samples were further hybridized with TNFa cDNA fragment
and a corresponding transcript of 1.7 kb was detected in seven
of them (Fig. 2). All these samples were obtained from clear cell
type carcinomas.
A low level of IL-i p mRNA transcripts were detected in the
seven tested tumors whereas IL-i a mRNA was not detected
(data not shown).
To further investigate if IL-6 and TNFa were expressed in
tumor cultured cells, Northern blots or RT-PCR were per-
formed on total cellular RNA extracted from seven RCC
derived cell cultures. As shown in Table 1, IL-6 mRNAs were
detected in five cases and TNFa mRNAs in four cases. It is of
note that all the three cases tested by RT-PCR expressed
consistent levels of IL-6 and TNFa specific mRNAs (Fig. 3).
Alcaline Southern transfer and probing with 32P-end-labeled
oligonucleotides identified the fragments as TNFa (355 pb) and
IL-6 (628 pb), respectively.
Immunohistochemistry
Normal kidney areas. Light microscopy examination did not
reveal any inflammatory or tumoral changes in these sections.
A low number of CD 14 positive interstitial macrophages was
present (less than 1 cell per microscopic field at x40 magnifi-
cation). CR1 antigen was detected at the membrane of glomer-
ular podocytes and on sparse interstitial cells. NK cells were
not detected. A faint staining was obtained with anti-IL-i ab on
the arteriolar endothelial cells. Vascular myocytes and glomer-
ular mesangial cell were positively stained. Anti-TNFa ab
stained arteriolar endothelia and smooth muscle cells, as well as
giomerular mesangial cells. Endothelial cells from peritubular
capillaries and tubular epithelial cells were negative. Anti-IL-6
ab stained smooth muscle cells in arterioles and glomerular
mesangial cells. Questionable staining was noted on some
glomerular parietal epithelial cells.
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Fig. 3. Detection of TNFa and IL-6 mRNAs in three RCC-derived cell
cultures (cases 5, 6 and 7) by RT-PCR. Total RNA (1 g) was extracted
and reverse-transcribed using random primers. The expected sizes of
PCR products for TNFa and IL-6 were 355 and 628 bp, respectively.
Tumors. Variable numbers of CD14 immunoreactive macro-
phages were detected in the stroma in all the 19 tumors; in ii
cases they were numerous (1 macrophage/5 to 10 tumoral cells).
Some NK cells (less than 6 cells per field at x 40) were present
in eight cases. Anti-F VIII antibody staining showed a rich
capillary network between the tumoral clumps in all cases (Fig.
4).
Negative staining using anti-IL-i ab was observed in 12 out of
19 cases. In the other seven cases some faint fixation was
observed on the endothelium of stromal blood capillaries; in
three of these cases some CDI4 immunoreactive interstitial
cells were also IL-I positive. IL-6 immunoreactivity was totally
negative in all cases except for the vascular myocytes. In
contrast, consistent staining was observed with anti-TNFa ab.
In all cases the endothelium of the stromal capillaries was
strongly labeled as well as some macrophages or other intersti-
tial cells (Fig. 4). In addition, staining of the tumoral cells
themselves was clearly observed in eight cases (2 basophiic cell
types and 6 clear cell types) predominantly localized at the
basal pole of the cells (Fig. 5). In the 11 remaining cases the
topography of anti-TNFa ab staining was difficult to define
since it delineated a branching network between the tumoral
clumps. In all the 19 cases we noted that the staining exhibited
with anti-INFa ab was more diffuse compared to the specific
labeling of macrophages and vessels (Fig. 4c).
RCC cultures. The results of the immunochemical analysis
summarized in Table 1 show that in all cases the majority of the
Fig. 4. Frozen sections of RCC immunostained for CDJ4, F VIII and
TNFa antibodies. Immunoreactivity was examined on serial sections
from the same area. A. CDI4 immunoreactivity (original magnification
X250). Note specific labeling of numerous macrophages present in the
supportive stroma. B. FVIII immunoreactivity (original magnification
x250). Staining pattern delineating the rich capillary network. C. TNFa
immunoreactivity (original magnification x250). Evidence for positive
staining of vessels, macrophages and tumor cells.
cells were CD24 positive. Cytokeratine immunoreactivity was
observed in six of the seven cell cultures (Fig. 6). IL-6 was not
detected, whereas in six cases the cells stained with anti-TNFa
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Fig. 5. TNFa immunoreactivisy in clear cell
type carcinoma (original magnification x400).
Note the labeling of the tumor cell membrane.
ab (Fig. 6). The cultured skin fibroblasts were vimentin positive
and were not stained with anti-IL-6 or anti-TNFa ab.
Levels of IL-6 and TNFa in culture supernatants
The seven culture supernatants collected at the second or
third passage were monitored for the production of IL-6. The
concentrations ranged from 500 to more than 1400 U/mi as
detected by the B9 bioassay (Table 1). To ascertain that
supernatant-induced B9 cell proliferation was due to IL-6,
samples with IL-6 activity were tested in the presence of
anti-IL-6 polyclonal antibody. Preincubation of the seven cul-
ture supernatants with this anti-IL-6 ab significantly reduced (77
to 85% of inhibition) the proliferation of the B9 cells, giving
evidence that the activity detected in supernatants was attrib-
utable to IL-6.
Determination of secreted TNFa in culture supernatants by
biological activity or immunoreactivity is shown in Table 1.
Measurable TNFa cytotoxic activity could not be detected in
any of the supernatants tested. However, significant levels of
immunoreactive TNFa protein was measured in two of three
unconcentrated supernatants (Table 1). Remarkably, TNFa
protein was not detected by ELISA and immunocytochemistry
in case 7.
Discussion
The present study demonstrates that the normal human
kidney constitutively expresses significant levels of TNFa and
IL-6 mRNA. Lower amounts of IL-l/3 specific mRNA were
also detectable. Immunoreactive IL-6, TNFa and IL-1f3 were
observed in the renal parenchyma mainly in the arteriole walls
and in the glomerular mesangial cells, but not in the tubular
cells. These findings are in agreement with those previously
reported concerning IL-6, TNFa and IL-l/3 expression in
normal kidney tissue at the RNA [8, 20] or protein level [21]. In
addition, it has recently been shown that normal renal tubular
epithelial cells in vitro spontaneously express IL-6 mRNA but
neither IL-l nor TNFa transcripts [22].
In RCC, we observed significant levels of TNFa and IL-6
RNA transcripts compared to the paired normal tissue, whereas
similar low levels of IL-l/3 specific transcripts were present in
both normal and tumoral tissue.
Although consistent levels of IL-6 RNA were observed in the
tumors, immunoreactive IL-6 was not detected in the RCC in
vivo, except in the normal arterial walls included in the tumor.
Likewise, cultured RCC cells were not stained with anti-IL-6
ab, in spite of the presence of IL-6 mRNA and of the measur-
able amounts of bioactive IL-6 protein in the culture superna-
tants. These data suggest that RCC cells produce IL-6 protein
both in vivo and in vitro, which is not stored in the producing
cells.
Constitutive production of IL-6 has been found in various
human tumors, including adenocarcinomas, soft tissue tumors
and lymphomas [23], as well as in epidermoid, ovarian and
bladder carcinoma cell lines [17, 24, 25]. In studies using cell
cultures derived from human RCC, it was found that tumoral
cells produce significant amounts of bioactive IL-6 protein in
vitro [9, 10, 26, 27], which is in agreement with our results.
However, these authors reported that variable percentages of
the tumoral cells either in vivo [26] or in vitro [9, 11] were IL-6
immunoreactive, which is in disagreement with our observa-
tions. This discrepancy could be due to the different origins or
specificities of the anti-IL-6 antibodies. Whatever the reasons
for these discordant immunohistochemical results, it can be
concluded that RCC cells produce IL-6 in vivo. In this regard,
the increased levels of serum acute phase reactant proteins
frequently observed in patients with RCC [7] could be related to
the IL-6 production by the neoplastic cells.
Concerning TNFa expression, our results indicate that the
consistent levels of TNFa mRNA detected in RCC are, at least
in part, related to the supportive stroma. Indeed, we observed
that infiltrating macrophages and the vascular network of the
supportive stroma were clearly stained by the anti-TNFa ab.
Similarly, TNFa mRNA synthesis has been evidenced by in
situ hybridization in activated macrophages present in colorec-
tal cancer stroma but not in the neopiastic cells [28]. The strong
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Fig. 6. Cytokeratin and TNFa
immunostaining of RCC cultures cells (Table
1, case 1) (original magn(fication x400). A.
Anticytokeratin immunoreactivity: evidence of
filamentous cytoplasmic staining. B. TNFa
immunoreactivity showing fine granular
pattern.
TNFa immunostaining of the stromal capillary vessels ob-
served in RCC is intriguing, since it was not observed in the
nontumoral areas of the corresponding kidney. Moreover, using
the same antibody and the same technical procedure, TNFa
staining of the renal blood capillaries was not observed in
inflammatory conditions, such as renal transplant acute rejec-
tion crisis or glomerulonephritis, while it was detected in
tubular cells (unpublished observations). Therefore, TNFa
immunostaining of capillary endothelial cells appears as partic-
ular feature of the RCC supportive stroma and could be related
to the intense neoangiogenesis present in these tumors. In this
respect, it has been reported that TNFa [29, 30] is a potent
activator of endothelial cells in vitro and plays a major role in
angiogenesis in vivo [31].
In addition to the observation that TNFa is produced by the
supportive stroma our results argue for tumoral cell production
of this cytokine. Indeed, in tumors, TNFa positive RCC cells
were clearly detected in 40% of the studied cases. Furthermore,
TNFa producing cells were directly identified by immunostain-
ing utilizing anti-TNFa ab in six of seven RCC derived cultures,
whereas specific TNFa transcripts were detected in four cases.
This discrepancy between the TNFa mRNA levels and the
presence of TNFa antigen in the cells might be related to the
transcriptional and post-transcriptional regulation of this mole-
cule [32]. It is of note that in our material the TNFa production
was evidenced in clear cell type tumors as well as in tubulo-
papillary tumors with basophilic cells.
Within the limits of the L929 assay, TNFa biological activity
was not detected in RCC culture supernatants while immuno-
reactive TNFa could be measured in two cases. These data
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suggest that either RCC cells in vitro synthesize inactive TNFa
or that the released active protein is rapidly inactivated or
degraded. It has recently been reported that normal renal
tubular epithelial cells, when stimulated by LPS, are able to
express TNFa transcripts [33, 34], whereas the levels of bioac-
tive TNFa measured in supernatants remained remarkably low,
suggesting that the cells express cell membrane associated and
secreted TNFa molecule [34]. Expression of TNFa mRNA has
also been documented in several long-term cultured epithelial
tumor cell lines, especially in those resistant to TNFa induced
cytotoxicity [35, 36]. Interestingly, it was observed that the cell
lines resistant to TNFa did not produce detectable amounts of
TNFa protein in vitro as evaluated by the L929 assay. How-
ever, after protein labeling and immunoprecipitation, TNF
product was detectable in supernatants and cell lysates from
ovarian carcinoma cells [37]. One hypothesis to explain all
these data would be that the TNFa molecule produced by the
cultured cells is complexed to its soluble receptors, and thus
has lost its biological activity [38]. Whether the TNFa protein
produced by the RCC cells in vivo is bioactive or not remains
unsolved. However, in addition to the frequency of tumor
necrosis, several facts such as the modulation of the expression
of HLA class I antigen [6], EGF-receptor [39] or ICAM-l and
VCAM adhesion molecules (unpublished observations) by the
tumor cells, could be related to the presence of bioactive TNFa
molecule.
In conclusion, we emphasize the TNFa and IL-6 cytokine
gene expression by RCC cells themselves as well as by the
supportive stroma. These findings may explain some of the
histopathological and clinical features observed in patients with
this malignancy, and highlight their involvement in RCC growth
and spread.
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